The predictive validity of subjective adherence measures in patients with schizophrenia

International Journal of Methods in Psychiatric Research

Volumn 20, Issue 2, 2011, Pages 73-81

  Kikkert, Martijn J ^a,b   Koeter, Maarten W J ^a   Dekker, Jack J M ^b   Burti, Lorenzo ^c   Robson, Debbie ^d   Puschner, Bernd ^e   Schene, Aart H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Arkin Mental Health Institute   (Netherlands)

^c UNIVERSITY OF VERONA   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Adherence assessment; Antipsychotics; Clinical course; Medication adherence; Schizophrenia

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL COOPERATION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTIVE VALUE; PSYCHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ADULT; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY;

EID: 79956351333     PISSN: 10498931     EISSN: 15570657     Source Type: Journal    
DOI: 10.1002/mpr.335     Document Type: Article

References (52)

1. Ascher-Svanum H., Zhu B., Faries D., Lacro J.P., Dolder C.R. (2006) A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. Journal of Clinical Psychiatry, 67(7), 1114-1123.
2. Ayuso-Gutierrez J.L., del Rio Vega J.M. (1997) Factors influencing relapse in the long-term course of schizophrenia. Schizophrenia Research, 28(2-3), 199-206.
3. Burti L., Mazzi M., Koeter M., Schene A., Helm H., Puschner B., Bindman J., Leese M., Thornicroft G., Tansella M. (2009) An empirical method to identify patterns in the course of psychotic episodes of people with schizophrenia. International Journal of Methods in Psychiatric Research, 18(4), 265-278.
4. Byerly M., Fisher R., Whatley K., Holland R., Varghese F., Carmody T., Magouirk B., Rush A. (2005) A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research, 133(2-3), 129-133. DOI: 10.1016/j.psychres.2004.11.002
5. Byerly M., Thompson A., Carmody T., Bugno R., Erwin T., Kashner M., Rush A.J. (2007) Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatric Services, 58(6), 844-847.
6. Cohen J. (1988) Statistical Power Analysis for Social Sciences (2nd ed.), Hillsdale, NJ, Lawrence Earlbaum Associates Inc.
7. Conley R.R., Kelly D.L. (2001) Management of treatment resistance in schizophrenia. Biological Psychiatry, 50(11), 898-911.
8. David A. (1990) Schedule for assessment of insight into psychosis. British Journal of Psychiatry, 156, 798-803.
9. Diaz E., Levine H.B., Sullivan M.C., Sernyak M.J., Hawkins K.A., Cramer J.A., Woods S.W. (2001) Use of the medication event monitoring system to estimate medication compliance in patients with schizophrenia. Journal of Psychiatry & Neuroscience, 26(4), 325-329.
10. Eaddy M., Grogg A., Locklear J. (2005) Assessment of compliance with antipsychotic treatment and resource utilization in a medicaid population. Clinical Therapeutics, 27(2), 263-272. DOI: 10.1016/j.clinth era.2005.02.003
11. Fenton W.S., Blyler C.R., Heinssen R.K. (1997) Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23(4), 637-651.
12. George C.F., Peveler R.C., Heiliger S., Thompson C. (2000) Compliance with tricyclic antidepressants: The value of four different methods of assessment. British Journal of Clinical Pharmacology, 50(2), 166-171.
13. Gilmer T.P., Dolder C.R., Lacro J.P., Folsom D.P., Lindamer L., Garcia P., Jeste D.V. (2004) Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaires with schizophrenia. American Journal of Psychiatry, 161(4), 692-699.
14. Gray R., Leese M., Bindman J., Becker T., Burti L., David A., Gournay K., Kikkert M., Koeter M., Puschner B., Schene A., Thornicroft G., Tansella M. (2006) Adherence therapy for people with schizophrenia: European multicentre randomized controlled trial. British Journal of Psychiatry, 189, 508-514. DOI: 10.1192/bjp.bp.105.019489
15. Haro J.M., Suarez D., Novick D., Brown J., Usall J., Naber D., the SOHO Study Group (2006) Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. European Neuropsychopharmacology, 17(4), 235-44. DOI: 10.1016/j.euroneuro.2006.09.005
16. Hogan T.P., Awad A.G., Eastwood R. (1983) A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychology Medicine, 13(1), 177-183.
17. Johnstone E.C. (1992) Relapse in schizophrenia; What are the major issues. In Hawton K. (ed.) Practical Problems in Clinical Psychiatry, Oxford, Oxford University Press.
18. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E., EUFEST Study Group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet, 371(9618), 1085-1097.
19. Kane J.M. (1983) Problems of compliance in the outpatient treatment of schizophrenia. Journal of Clinical Psychiatry, 44(6 Pt 2), 3-6.
20. Kane M. (1996) Treatment resistant schizophrenic patients. Journal of Clinical Psychiatry, 57(Suppl. 9), 35-40.
21. Kane M. (1999) Management strategies for the treatment of schizophrenia. Journal of Clinical Psychiatry, 60(Suppl. 12), 13-17.
22. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., Schimmelmann B.G., Naber D. (2007) Association of subjective well-being, symptoms, and side effects with compliance after 12months of treatment in schizophrenia. Journal of Clinical Psychiatry, 68(1), 75-80.
23. Keith S.J., Kane J.M. (2003) Partial compliance and patient consequences in schizophrenia: Our patients can do better. Journal of Clinical Psychiatry, 64(11), 1308-1315.
24. Kemp R., David A. (1996) Psychological predictors of insight and compliance in psychotic patients. British Journal of Psychiatry, 169(4), 444-450.
25. Kemp R., Kirov G., Everitt B., Hayward P., David A. (1998) Randomised controlled trial of compliance therapy. British Journal of Psychiatry, 172, 413-419.
26. Kikkert M.J., Barbui C., Koeter M.W.J., David A.S., Leese M., Tansella M., Gießler A., Puschner B., Schene A.H. (2008) Assessment of medication adherence in patients with schizophrenia: The Achilles heel of adherence research. The Journal of Nervous and Mental Disease, 196(4), 274-281. DOI: 10.1097/NMD.0b013e31816a4346
27. Kleinbaum D.G. (1990) Survival Analysis: A Self Learning Text, New York, Springer-Verlag.
28. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209-1223.
29. Malla A., Norman R., Schmitz N., Manchanda R., Bechard-Evans L., Takhar J., Haricharan R. (2006) Predictors of rate and time to remission in first-episode psychosis: A two-year outcome study. Psychology Medicine, 36(5), 649-658. DOI: 10.1017/S0033291706007379
30. Maldonado G., Greenland S. (1993) Simulation study of confounder-selection strategies. American Journal of Epidemiology, 138(11), 923-936.
31. Morisky D.E., Green L.W., Levine D.M. (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24(1), 67-74.
32. Morken G., Widen J.H., Grawe R.W. (2008) Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry, 8, 32. DOI: 10.1186/1471-244X-8-32
33. Mutsatsa S.H., Joyce E.M., Hutton S.B., Webb E., Gibbins H., Paul S., Barnes T.R.E. (2003) Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatrica Scandinavica, 108(6), 439-446.
34. Nichol M.B., Venturini F., Sung J.C.Y. (1999) A critical evaluation of the methodology of the literature on medicatin compliance. Annals of Pharmacotherapy, 33(5), 531-540.
35. Nose M., Barbui C., Tansella M. (2003) How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine, 33(7), 1149-1160. DOI: 10.1017/S0033291703008328
36. Osterberg L., Blaschke T. (2005) Adherence to medication. New England Journal of Medicine, 353(5), 487-497.
37. Perkins D.O. (2002) Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry, 63(12), 1121-1128.
38. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A., Comparison of Atypicals in First Episode Study Group (2008) Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study. Journal of Clinical Psychiatry, 69(1), 106-113.
39. Pinikahana J., Happell B., Taylor M., Keks N.A. (2002) Exploring the complexity of compliance in schizophrenia. Issues in Mental Health Nursing, 23(5), 513-528. DOI: 10.1080/0161284029005267 7
40. Remington G., Kwon J., Collins A., Laporte D., Mann S., Christensen B. (2007) The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophrenia Research, 90(1-3), 229-237. DOI: 10.1016/j.schres.2006.11.015
41. Robinson D., Woerner M.G., Alvir J.M.J., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman A. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56(3), 241-247.
42. Roth M.T., Ivey J.L. (2005) Self-reported medication use in community-residing older adults: A pilot study. American Journal of Geriatric Pharmacotherapy, 3(3), 196-204. DOI: I0 I016/j amjopharm 2005 09 009
43. Rothman K.J., Greenland S. (1998) Modern Epidemiology (2nd ed.), New York, Lippincott Raven Publishers.
44. Ruggeri M., Koeter M.W.J., Schene A.H., Bonetto C., Vazquez-Barquero J.L., Becker T., Knapp M., Knudson H.C., Tansella M., Thornicroft G., EPSILON Study Group (2005) Factor solution of the BPRS-expanded version in schizophrenic outpatients living in five European countries. Schizophrenia Research, 75(1), 107-117. DOI: 10.1016/j.schres.2004.05.017
45. Sabaté E. (2003) Adherence to Long Term Therapies: Evidence for Action, Geneva, World Health Organization.
46. Sonis J. (1998) A closer look at confounding. Family Medicine, 30(8), 584-588.
47. Valenstein M., Copeland L.A., Blow F.C., McCarthy J.F., Zeber J.E., Gillon L., Bingham C.R., Stavenger T. (2002) Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care, 40(8), 630-639. DOI: 10.1097/01.MLR.0000021003.43524.64
48. Velligan D.I., Lam Y.W.F., Glahn D.C., Barrett J.A., Maples N.J., Ereshefsky L., Miller A.L. (2006) Defining and assessing adherence to oral antipsychotics: A review of the literature. Schizophrenia Bulletin, 32(4), 724-742. DOI: 10.1093/schbul/sbj075
49. Weiden P.J., Kozma C., Grogg A., Locklear J. (2004) Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services, 55(8), 886-891.
50. Weiden P.J., Zygmunt A. (1997) The road back: Working with the severely mentally ill. Medication noncompliance in schizophrenia: I. Assessment. Journal of Practical Psychiatry and Behavioral Health, March 1997, 106-110.
51. Wing J.K., Babor T., Brugha T., Burke J., Cooper J.E., Giel R., Jablenski A., Regier D., Sartorius N. (1990) SCAN. Schedules for clinical assessment in neuropsychiatry. Archives of General Psychiatry, 47(6), 589-593.
52. World Health Organization (WHO) (2003) WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC classification and DDD assignment, Oslo, WHO.